Lantern Pharma Completes LP-184 Trial, 63 Patients Show Promising Efficacy
Lantern Pharma announced additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 as well as highlights from its recent webinar. The clinical trial demonstrated durable disease control in 63 heavily pre-treated patients with advanced solid tumors, many of which had DNA damage repair pathway deficiencies. The clinical trial met all primary endpoints for safety, tolerability, and established a clear recommended phase 2 dose. Building on these Phase 1a results, Lantern is advancing an ambitious precision oncology development strategy featuring multiple biomarker-guided Phase 1b/2 clinical trials in triple-negative breast cancer, glioblastoma multiforme, non-small cell lung cancer and advanced urothelial carcinoma. Overall, 63 heavily pre-treated patients with advanced solid tumors enrolled; trial achieved 54% disease control rate in patients at or above therapeutic dose levels, demonstrating promising activity in DNA damage repair-deficient cancers. Patients with stage 4 squamous lung cancer, thymic carcinoma, and gastrointestinal stromal tumor remain on treatment with 12+ to 23+ months of ongoing clinical benefit and meaningful tumor reductions after failing multiple prior therapies. Lantern's Radr platform identified PTGR1 as a key predictive biomarker; greater than 87% of Phase 1a patients exceeded the bioactivation threshold, with a diagnostic-ready molecular assay enabling patient selection and/or stratification. The Phase 1a study enrolled 63 patients with advanced solid tumors who had received a median of three prior lines of therapy. A 62-year-old male patient with stage 4 squamous NSCLC harboring a BRCA1 alteration, who had failed radiation and durvalumab, began LP-184 treatment in December 2023 and continues on therapy with more than 23 months of clinical benefit and 22% target lesion reduction. A 50-year-old male patient with stage 4 thymic carcinoma with a CHEK2 alteration, who had progressed through four prior lines including pembrolizumab, started LP-184 in November 2023 and remains on treatment with more than 12 months of benefit and 26% target lesion reduction. A 62-year-old female patient with stage 4 gastrointestinal stromal tumor harboring an ATM alteration, who had failed four prior therapies including sunitinib, initiated LP-184 in November 2023 and continues treatment with more than 12 months of benefit and 9% tumor reduction. The trial met all primary endpoints for safety and tolerability and established a clear Recommended Phase 2 Dose with a wide therapeutic window.
Trade with 70% Backtested Accuracy
Analyst Views on LTRN
About LTRN
About the author
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors
Clinical Study Results: Lantern Pharma's Phase 1a dose-escalation study of LP-184 demonstrated promising disease control in patients with advanced solid tumors and DNA damage repair deficiencies, meeting all safety and tolerability endpoints.
Future Plans: The company intends to progress LP-184 into multiple Phase 1b/2 trials following the successful outcomes of the initial study.
Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.
Clinical Success of LP-284: LP-284, an AI-driven drug candidate, achieved a complete metabolic response in a patient with aggressive B-cell lymphoma after just two cycles, validating its synthetic lethal mechanism and addressing treatment gaps for patients who have failed CAR-T and bispecific therapies.
Strategic Partnership Potential: The drug's profile presents significant partnership opportunities for biopharmaceutical companies, particularly due to its novel mechanism that overcomes resistance to current therapies and demonstrates preclinical synergy with existing FDA-approved agents like rituximab.
Market Need and Economic Impact: With approximately 200,000 new DLBCL cases diagnosed annually and high post-relapse treatment costs, LP-284's off-the-shelf administration could alleviate both clinical and economic burdens in the post-immunotherapy setting.
Ongoing Development and Future Prospects: Lantern Pharma is advancing LP-284 through a Phase 1 trial while exploring combination therapy opportunities, with plans for further clinical assessments and potential expansion into autoimmune and inflammatory conditions.
Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025
Company Presentation: Lantern Pharma Inc. will present at the ThinkEquity Conference on October 30, 2025, at 11:30 a.m. ET in New York, NY, with opportunities for one-on-one meetings available throughout the event.
AI-Driven Drug Development: The company utilizes its proprietary AI platform, RADR®, to enhance oncology drug discovery and development, aiming to address significant challenges in the field and potentially impacting over $15 billion in market potential.
Clinical Programs: Lantern Pharma is advancing multiple clinical programs, including a Phase 2 program and several Phase 1 trials, targeting various cancer types with the goal of providing innovative therapies to patients.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and drug development plans, highlighting potential risks and uncertainties that could affect outcomes.
Lantern Pharma Reports Positive Safety and Initial Efficacy Results for Cancer Drug in Phase 1 Trial
Phase 1a Trial Announcement: Lantern Pharma (LTRN) announced a phase 1a trial to evaluate its drug LP-184 as a potential treatment.
Sign-in Requirement: Users need to sign in to access their portfolio related to the trial or company updates.
Lantern Pharma Reports Successful Phase 1a Study of LP-184 in Advanced Solid Tumors, Achieving All Primary Endpoints
Phase 1a Study Results: Lantern Pharma's LP-184 drug candidate met all primary endpoints in a Phase 1a study for patients with advanced solid tumors, including Glioblastoma Multiforme (GBM).
Next Steps in Development: The drug demonstrated a strong safety profile and early signs of antitumor activity, leading to plans for targeted Phase 1b and Phase 2 studies using the RADR AI platform.
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors
Clinical Study Results: Lantern Pharma's Phase 1a dose-escalation study of LP-184 demonstrated promising disease control in patients with advanced solid tumors and DNA damage repair deficiencies, meeting all safety and tolerability endpoints.
Future Plans: The company intends to progress LP-184 into multiple Phase 1b/2 trials following the successful outcomes of the initial study.
Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.
Clinical Success of LP-284: LP-284, an AI-driven drug candidate, achieved a complete metabolic response in a patient with aggressive B-cell lymphoma after just two cycles, validating its synthetic lethal mechanism and addressing treatment gaps for patients who have failed CAR-T and bispecific therapies.
Strategic Partnership Potential: The drug's profile presents significant partnership opportunities for biopharmaceutical companies, particularly due to its novel mechanism that overcomes resistance to current therapies and demonstrates preclinical synergy with existing FDA-approved agents like rituximab.
Market Need and Economic Impact: With approximately 200,000 new DLBCL cases diagnosed annually and high post-relapse treatment costs, LP-284's off-the-shelf administration could alleviate both clinical and economic burdens in the post-immunotherapy setting.
Ongoing Development and Future Prospects: Lantern Pharma is advancing LP-284 through a Phase 1 trial while exploring combination therapy opportunities, with plans for further clinical assessments and potential expansion into autoimmune and inflammatory conditions.
Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025
Company Presentation: Lantern Pharma Inc. will present at the ThinkEquity Conference on October 30, 2025, at 11:30 a.m. ET in New York, NY, with opportunities for one-on-one meetings available throughout the event.
AI-Driven Drug Development: The company utilizes its proprietary AI platform, RADR®, to enhance oncology drug discovery and development, aiming to address significant challenges in the field and potentially impacting over $15 billion in market potential.
Clinical Programs: Lantern Pharma is advancing multiple clinical programs, including a Phase 2 program and several Phase 1 trials, targeting various cancer types with the goal of providing innovative therapies to patients.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and drug development plans, highlighting potential risks and uncertainties that could affect outcomes.
Lantern Pharma Reports Positive Safety and Initial Efficacy Results for Cancer Drug in Phase 1 Trial
Phase 1a Trial Announcement: Lantern Pharma (LTRN) announced a phase 1a trial to evaluate its drug LP-184 as a potential treatment.
Sign-in Requirement: Users need to sign in to access their portfolio related to the trial or company updates.
Lantern Pharma Reports Successful Phase 1a Study of LP-184 in Advanced Solid Tumors, Achieving All Primary Endpoints
Phase 1a Study Results: Lantern Pharma's LP-184 drug candidate met all primary endpoints in a Phase 1a study for patients with advanced solid tumors, including Glioblastoma Multiforme (GBM).
Next Steps in Development: The drug demonstrated a strong safety profile and early signs of antitumor activity, leading to plans for targeted Phase 1b and Phase 2 studies using the RADR AI platform.
